Kevin Schwartz

Jan 11, 2025 | qualitysafety.bmj.com | Bradley J. Langford |Kevin Schwartz

Audit and feedbackGeneral practiceHealth policyImplementation sciencePrimary careAntimicrobial resistance (AMR) has quietly become a global health crisis, claiming 1.1 million lives annually as of 2021. If left unchecked, the death toll is forecasted to climb to 1.9 million per year by 2050.1Despite the mounting volume of data on the burden of AMR, the global response has been sluggish with limited progress.

Jun 5, 2024 | bmj.com | Kevin Schwartz |Jennifer Shuldiner |Bradley J. Langford |Kevin Brown

Research BMJ 2024; 385 doi: https://doi.org/10.1136/bmj-2024-079329 Cite this as: BMJ 2024;385:e079329 Linked Editorial Antimicrobial stewardship Kevin L Schwartz, assistant professor1 2 3 4, Jennifer Shuldiner, doctoral student5 6, Bradley J Langford, assistant professor1 3, Kevin A Brown, associate professor1 2 3, Susan E Schultz, senior analyst2, Valerie Leung, pharmacist1 7, Nick Daneman, professor1 2 6 8, Mina Tadrous, assistant professor2 5 9, Holly O Witteman, associate professor10 11,...

Feb 13, 2023 | dispatchist.com | Kevin Schwartz

Paxlovid reduced hospitalisation, death risk during Omicron wave: Study The researchers found that for every 62 people treated with nirmatrelvirritonavir, the medication prevented one case of severe COVID-19 strong Coronavirus | Omicron Photo: Bloomberg ALSO READ Pfizer CEO rules out talk with China on generic Covid drug Paxlovid license Pfizer's Paxlovid antiviral lowered long-Covid risk, suggests study China, Pfizer hit deadlock over Paxlovid's price amid Covid-19 surge Hyderabad-based drug...

Feb 13, 2023 | cmaj.ca | Kevin Schwartz |Jun Wang |Mina Tadrous |Bradley J. Langford

InterpretationWe found that the use of nirmatrelvir–ritonavir in Ontario between April and August 2022 was associated with a significant reduction in the odds of hospital admission from COVID-19 or all-cause death with a NNT of 62. Our findings were consistent across most strata of age, drug–drug interactions, vaccination status and comorbidities; however, the absolute risk reductions were substantially lower in younger patients and those at lower risk of severe COVID-19.